Grifols, S.A. GRFS

Full chart Compare
Set alert

Price alert · GRFS

All alert types
8.61 USD +0.05 (+0.58%)

At closeNov 4, 2026, 4:04 PM EST

8.55 -0.06 -0.71%

After hours · Nov 4, 4:04 PM ET

8.38 Day range 8.64
6.96 52-week range 9.77
YTD
-7.91%
1 year
-6.62%
Market cap
5.86B
Revenue (ttm)
7.60B
Profit margin
6.44%
EPS (ttm)
0.83
Shares out
258.22M
P/E ratio
10.37
Forward P/E
6.92
Dividend
0.11 (1.24%)
Ex-dividend date
Jul 1, 2026
YTD return
-7.91%
1-year return
-6.62%
Volume
674.60K
Avg volume
560.48K
Open
8.63
Previous close
8.56
Day's range
8.38 – 8.64
52-week range
6.96 – 9.77
Analysts
Buy
Price target
10.37 (+20.4%)
Earnings date
Mar 4, 2027

2Y -0.69 (-7.43%)

810Jan 25Jun 25Nov 25Apr 26Aug 268.60

Key statistics

Enterprise value
22.86B
PEG ratio
0.19
Price / sales
0.77
Price / book
0.99
Dividend yield
1.24%
Payout ratio
12.74%
Revenue growth
9.40%
Free cash flow
194.45M
Total cash
486.00M
Total debt
9.24B
Return on equity
7.33%
Short % of float
0.00%
50-day average
7.61
200-day average
7.99

Financials — quick view

All financials
GRFS Revenue — annual 7.52B
2010-FY 20102011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
GRFS Net income — annual 402.00M
2010-FY 20102011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025
GRFS EPS — annual 0.59
2010-FY 20102011-FY 20112012-FY 20122013-FY 20132014-FY 20142015-FY 20152016-FY 20162017-FY 20172018-FY 20182019-FY 20192020-FY 20202021-FY 20212022-FY 20222023-FY 20232024-FY 20242025-FY 2025

Earnings

GRFS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 4, 2027Dec 30, 20260.3312———
Nov 2, 2026Sep 30, 20260.32020.3359+0.02+4.90%
Jul 28, 2026Jun 30, 20260.270.2512-0.02-6.96%
May 7, 2026Mar 31, 20260.16130.1731+0.01+7.32%
Feb 26, 2026Dec 31, 20250.290.28910.00-0.31%
Nov 4, 2025Sep 30, 20250.24170.2108-0.03-12.78%

Upgrades / downgrades

GRFS analyst upgrades and downgrades
DateFirmActionFromTo
Oct 26, 2026JP MorganmainNeutralNeutral
Dec 8, 2025JP MorganmainNeutralNeutral
Jun 17, 2025JP MorganmainNeutralNeutral
Mar 12, 2024Deutsche BankdownHoldSell
Dec 5, 2023JP MorganmainNeutralNeutral
Nov 5, 2021Deutsche BankdownBuyHold

About Grifols, S.A.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
Spain
Website
grifols.com

News

Your note

Sign in to keep a note on GRFS — it syncs with the Stock Master app.

Institution ownership

GRFS institution ownership
Holder% heldSharesValueReported
Brandes Investment Partners L.P.14.47%37,816,285325.60MJun 29, 2026
Capital World Investors8.76%22,911,656197.27MJun 29, 2026
Permian Investment Partners, Lp7.55%19,740,679169.97MJun 29, 2026
Black Creek Investment Management Inc.2.94%7,682,05566.14MJun 29, 2026
Bank of America Corporation2.51%6,550,33756.40MJun 29, 2026
Millennium Management Llc1.67%4,369,93437.63MJun 29, 2026

Fund ownership

GRFS fund ownership
Holder% heldSharesValueReported
NEW PERSPECTIVE FUND5.37%14,039,027120.88MSep 29, 2026
Intl Growth & Income Fd.-Intl Growth and Income Fd.1.98%5,180,41644.60MSep 29, 2026
Brandes Investment Trust-BRANDES INTERNATIONAL SMALL CAP EQUITY FUND1.84%4,803,45941.36MJun 29, 2026
iShares Trust-iShares Biotechnology ETF0.69%1,812,12615.60MSep 29, 2026
Brandes Investment Trust-BRANDES SMALL CAP VALUE FUND0.63%1,647,43814.18MJun 29, 2026
2023 ETF Series Trust-Brandes International ETF0.34%893,1537.69MJun 29, 2026